MedTrace Logo

Ginkgo Biloba Prevention Trial in Older Individuals

NCT00010803 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3069

Last updated 2013-03-14

Study results available
· View outcomes & findings →

Summary

This study will determine the effect of 240mg/day Ginkgo biloba in decreasing the incidence of dementia and specifically Alzheimer's disease (AD), slowing cognitive decline and functional disability, reducing incidence of cardiovascular disease, and decreasing total mortality.

Conditions

Interventions

DRUG

Ginkgo biloba

120mg twice a day

DRUG

Placebo

One pill twice daily

Sponsors & Collaborators

  • Office of Dietary Supplements (ODS)

    collaborator NIH

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • National Institute on Aging (NIA)

    collaborator NIH

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • National Center for Complementary and Integrative Health (NCCIH)

    lead NIH

Principal Investigators

  • Steven T. DeKosky, M.D. · University of Pittsburgh, Department of Neurology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2000-10-31
Primary Completion
2008-04-30
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00010803 on ClinicalTrials.gov